SCHEMBL3583252

SCHEMBL3583252

CC(C)(C)OC(=O)N[C@](C)(CCCc1ccc(Sc2cccc(C(F)(F)F)c2)cc1F)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.37
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
XBP1 P17861 1/20 0.35
RXRA P19793 4/20 0.35
NR1H2 P55055 4/20 0.35
GAA P10253 2/20 0.34
POLB P06746 1/20 0.34
MMP13 P45452 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
NR1H3 Q13133 2/20 0.33
SLC6A3 Q01959 1/20 0.33
RORC P51449 1/20 0.33
DDR1 Q08345 1/20 0.33
PTGES O14684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583255 1.00 SIRT2 (0.37) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL15310409 0.90 SIRT2 (0.37) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3301977 0.90 SIRT2 (0.37) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3298164 0.88 SIRT2 (0.37) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3298161 0.88 SIRT2 (0.37) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3583777 0.83 SIRT2 (0.37) SIRT2ATML3MBTL1ALDH1A1KDM4E
SCHEMBL4416807 0.82 RXFP1 (0.34) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL4336660 0.82 RXFP1 (0.34) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3301987 0.81 ATM (0.36) SIRT2ATML3MBTL1RXFP1ALDH1A1
SCHEMBL3301980 0.81 ATM (0.36) SIRT2ATML3MBTL1RXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2053038-B1 AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESSIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT KYORIN SEIYAKU KK (JP) 2016-10-05 EP disclosed
US-8273748-B2 Amino alcohol derivative and immunosuppresive agent having same as an active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-09-25 US disclosed
US-8232319-B2 Amino phosphate derivative and S1P receptor modulator having same as an active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-07-31 US disclosed
US-20100010000-A1 AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 US disclosed
US-20090325907-A1 AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2058317-A1 AMINOPHOSPHORIC ACID ESTER DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2009-05-13 EP disclosed
EP-2053038-A1 AMINOALCOHOL DERIVATIVE AND IMMUNOSUPPRESSANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2009-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325907-A1 AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT S1PR1, S1PR2, S1PR5 SIRT2 2716/4885ATM 1772/4885L3MBTL1 4576/4885
US-20100010000-A1 AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT ALDH7A1, AADAT, IDO1 SIRT2 2251/4885ATM 1489/4885L3MBTL1 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.